ANN ARBOR, Mich., Oct. 3, 2017 /PRNewswire/ -- Strata Oncology,
Inc. (Strata), a precision oncology company, announced a
collaboration with the University of
California San Francisco (UCSF) to launch Stratify
Prostate™ a unique initiative focused on expanding
access to tumor sequencing nationwide for men with advanced
prostate cancer and to dramatically accelerate enrollment into
relevant targeted therapy trials.
With the launch of this new initiative, eligible metastatic
prostate cancer patients anywhere in the
United States can now receive no-cost NGS testing via
enrollment in the Strata Trial, an observational study sponsored by
Strata, to study the impact of sequencing on clinical trial
enrollment. The larger Strata Trial is available to advanced cancer
patients with solid tumors and lymphomas, including prostate
cancer. The Strata Trial was launched in February of 2017 at select
clinical research sites, providing no-cost tumor sequencing to help
identify trial candidates for targeted therapies. Stratify Prostate
allows physicians who are not affiliated with these investigative
centers to offer their eligible patients with advanced prostate
cancer access to tumor sequencing.
As part of the collaboration, UCSF physicians and researchers
will play a leading role in driving success of Stratify Prostate,
and will use insights gained from the initiative to catalyze new
advances in prostate cancer.
"We are pleased to launch the Stratify Prostate initiative in
collaboration with Strata Oncology. This is a terrific example of
how UCSF clinicians and researchers provide patients with the most
up to date information and treatment options," said Eric Small, MD, deputy director of UCSF's Helen
Diller Family Comprehensive Cancer Center.
The StrataNGS™ Test is a 90-gene targeted assay
focused on actionable genetic alterations, sequences DNA and RNA on
limited archival or fresh biopsy material, and has a turnaround
time of less than 10 business days. Testing is performed in
Strata's high-throughput CLIA-certified lab in Ann Arbor, MI.
"We are excited to partner with UCSF to deliver on the promise
of precision medicine for men with advanced prostate cancer. Our
shared goal is to provide advanced patients the opportunity to be
tested without the worry of cost or location. With
innovations like Stratify Prostate™ and the larger
Strata Trial, our aim is to establish highly efficient ways for
physicians and their patients to get actionable genetic information
and real-time connections to targeted therapies," said Dan Rhodes, Ph.D., CEO of Strata.
The first clinical trials targeted in Stratify
Prostate™ are TRITON2 and TRITON3, evaluating Clovis
Oncology's PARP inhibitor rucaparib in metastatic
castration-resistant prostate cancer. Rucaparib was given
accelerated approval by the FDA in late 2016 for the treatment of
patients with deleterious BRCA mutation associated advanced ovarian
cancer. Additional trials for prostate cancer targeted therapy will
be evaluated for inclusion in Stratify Prostate.
Stratify Prostate is open to physicians and patients nationwide.
Interested participants should visit www.stratifyprostate.com to
learn more.
About Strata Oncology, Inc.
Strata Oncology is a
precision medicine company dedicated to transforming cancer care by
expanding patient access to precision medicine clinical trials. The
Strata Trial provides no-cost tumor sequencing to patients with
advanced cancer, while offering pharmaceutical companies exclusive
access to stratified patient populations to shorten clinical
development timelines. Strata aims to accelerate the approval of
new medicines for cancer patients by bringing together a
collaborative network of key stakeholders including patients,
providers and pharmaceutical companies. For more information visit
www.strataoncology.com
Media Inquiries:
Strata Oncology Media Relations
media@strataoncology.com
734.527.1000
View original
content:http://www.prnewswire.com/news-releases/strata-oncology-inc-announces-partnership-with-ucsf-to-launch-stratify-prostate-initiative-to-expand-access-to-precision-medicine-clinical-trials-for-10000-men-with-metastatic-prostate-cancer-300530100.html
SOURCE Strata Oncology, Inc.